Rein Therapeutics Inc. (RNTX)
NASDAQ · Healthcare
Rein Therapeutics Inc. EBITDA 2015–2025
Rein Therapeutics Inc. annual/quarterly ebitda history and growth rate from 2015 to 2025. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Rein Therapeutics Inc. ebitda for the quarter ending March 31, 2025 was -5.6 M, a 21.51% decrease year-over-year.
- Rein Therapeutics Inc. ebitda for the twelve months ending March 31, 2025 was -26.1 M, a 9.34% decrease year-over-year.
- Rein Therapeutics Inc. annual ebitda for 2025 was -50.6 M, a 22.17% decrease from 2024.
- Rein Therapeutics Inc. annual ebitda for 2024 was -65.0 M, a 302.61% increase from 2023.
- Rein Therapeutics Inc. annual ebitda for 2023 was -16.2 M, a 41.20% decrease from 2022.
- Rein Therapeutics Inc. annual ebitda for 2022 was -27.5 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Rein Therapeutics Inc. EBITDA — FAQ
Rein Therapeutics Inc. (RNTX) ebitda over the last 11 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see RNTX's ebitda history?
The chart and table above show Rein Therapeutics Inc.'s ebitda by year and by quarter, including the growth rate.